US 12358892
Metalloenzyme inhibitors for treating cancers, Alzheimer's disease, hemochromatosis, and other disorders
granted A61PA61P29/00A61P35/00
Quick answer
US patent 12358892 (Metalloenzyme inhibitors for treating cancers, Alzheimer's disease, hemochromatosis, and other disorders) held by Miralogx LLC expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Miralogx LLC
- Grant date
- Tue Jul 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 2
- CPC classes
- A61P, A61P29/00, A61P35/00